Skip to Main Content

Paper Details

Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.
Proc Natl Acad Sci U S A
50
2017
1 integrin, FN, Tumor, Tumor cells, VEGF, VEGFR2, amino acids, bevacizumab, breast cancer, c-Met, c-Met/1, c-Met/1 complex, cancer, fibronectin, glioblastoma, high-affinity 1 integrin, integrin, integrin-linked kinase, patient, site, tumor, tumor cells, xenograft models
Angiogenesis Inhibitors, Animals, Apoptosis, Bevacizumab, Breast Neoplasms, Cell Adhesion, Cell Movement, Drug Resistance, Neoplasm, Female, Fibronectins, Glioblastoma, Humans, Integrin beta1, Mice, Neoplasm Invasiveness, Phosphorylation, Proto-Oncogene Proteins c-met, Signal Transduction, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Author NameAffiliation
Arman JahangiriDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Alan T NguyenDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Ankush ChandraDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Maxim SidorovDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Garima YagnikDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Jonathan W RickDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Sung Won HanDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
William ChenDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Patrick M FlaniganDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Dina Schneidman-DuhovnyUniversity of California san francisco
Dina Schneidman-DuhovnyDepartment of Pharmaceutical Chemistry, University of California san francisco
Dina Schneidman-DuhovnyUniversity of California san francisco
Dina Schneidman-DuhovnyDepartment of Pharmaceutical Chemistry, University of California san francisco
Smita MascharakDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Michael De LayDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Brandon S ImberDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Catherine C ParkUniversity of California san francisco
Kunio MatsumotoCancer Research Institute, Kanazawa University
Kan V LuDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Gabriele BergersDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
Andrej Sali (CM4AI)University of California san francisco
Andrej Sali (CM4AI)California Institute for Quantitative Biosciences (QB3), University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, University of California san francisco
Andrej Sali (CM4AI)University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, University of California san francisco
Andrej Sali (CM4AI)California Institute for Quantitative Biosciences (QB3), University of California san francisco
William A WeissUniversity of California san francisco
William A WeissUniversity of California san francisco
Manish K AghiDepartment of Neurosurgery and Brain Tumor Research Center, University of California san francisco
  • 1 - 29

Datasets

Release 1.2